Peptide · Fact sheet
GHK-Cu
Also known as copper tripeptide-1 · copper peptide GHK-Cu
GHK-Cu is a copper-binding tripeptide studied in skin, wound, and hair biology. It is not an FDA-approved drug for wound healing, hair loss, anti-aging, or systemic use, and evidence depends heavily on formulation and route.
What is GHK-Cu?
GHK-Cu is a complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine with copper.
A topical cosmetic ingredient, an experimental wound product, and an injected compounded product are different exposures with different evidence and risks.
Benefits people look for
Laboratory and animal studies report effects on collagen, extracellular matrix, inflammation, and tissue-repair signaling.
It appears in skin-care and hair-growth marketing, where evidence for an ingredient is often stretched into claims about a specific finished product or systemic therapy.
What the evidence supports
- Animal wound models report increased collagen and extracellular-matrix accumulation.
- Small cosmetic studies and ingredient research suggest possible skin effects, but results are formulation-specific and not equivalent to an approved medical treatment.
All research areas
- Collagen and extracellular-matrix signaling
- Wound repair in animal models
- Skin appearance and photoaging
- Hair-follicle biology
- Topical skin and wound applications
- Hair-growth and follicle biology
- Tissue-repair signaling
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Itching after adding a copper-peptide skin product
A skincare user reported an itchier face after adding copper peptides to a routine that already contained several other products.
The full product formula and cause of irritation were not verified. A topical multi-ingredient experience cannot establish an allergy to GHK-Cu or describe systemic exposure.
Read the skincare account ↗Side effects & risks
- FDA identifies potential immune reactions, aggregation, and peptide-related impurity concerns for compounded injectable GHK-Cu.
- Human systemic safety data are limited, and cosmetic tolerability does not establish safety by another route.
- Copper exposure, formulation ingredients, contamination, and product mislabeling can change risk.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchMuch of the mechanistic and wound-healing evidence comes from cells or animals. Limited cosmetic research cannot establish broad medical, hair-growth, or systemic anti-aging claims.
Selected research to read
Animal wound-chamber study showing extracellular-matrix effects; not proof of human clinical benefit.
FDA approval & research status
No GHK-Cu drug product is FDA approved for wound healing, hair growth, anti-aging, or systemic use. FDA identifies potential immune and impurity risks for compounded injectable GHK-Cu and limited human safety data.
No FDA-approved use is documented in the records summarized on this page.
Preclinical and formulation-specific research
GHK-Cu has cosmetic and wound-healing biology, but no FDA-approved drug product for wound healing, hair growth, anti-aging, or systemic use.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether any finished product produces clinically meaningful wound or hair outcomes
- Long-term topical and systemic safety across formulations
- Whether laboratory signaling changes translate into visible or functional benefit
- Quality and identity of unapproved products marketed under the name
The takeaway
GHK-Cu is a plausible cosmetic and wound-research ingredient, not a single proven anti-aging or healing therapy. The finished formulation, route, outcome, and human trial matter.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2pubmedGHK-Cu wound study in rats
Animal wound-chamber study showing extracellular-matrix effects; not proof of human clinical benefit.
- 3fdaFDA: 503A bulk-substance status for GHK-Cu
FDA status document distinguishing non-injectable evaluation from injectable safety concerns.
- 4fdaFDA: understanding the risks of compounded drugs
FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.